Archives: 2019-09-11

PIER MARIA FORNASARI
2019-09-11

Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke

Background and Purpose— Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous allogeneic mesenchymal stem cells in this population. Methods— Entry criteria included ischemic stroke >6 months prior and substantial impairment (National

Read More

No Comments InBRAIN
PIER MARIA FORNASARI
2019-09-11

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer

Source https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(19)30339-X?elqTrackId=39785ec7f12f4ed79ff115249bc871f5&elq=81c0af21c850457daca48d5be457f158&elqaid=26028&elqat=1&elqCampaignId=10599 Invariant natural killer T (iNKT) cells are potent immune cells for targeting cancer; however, their clinical application has been hindered by their low numbers in cancer patients. Here, we developed a proof-of-concept for hematopoietic stem cell-engineered iNKT (HSC-iNKT) cell therapy with the potential to provide therapeutic levels of iNKT cells for a patient’s

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-09-11

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018

The majority of marketing authorizations granted through two expedited assessment pathways in Europe are based on non-validated surrogate endpoints rather than clinical outcomes, according to a study published September 10 in the open-access journal PLOS Medicine by Patricia McGettigan of Queen Mary University of London, and colleagues. The approval of new pharmaceutical products addressing an unmet need

Read More

No Comments InEMA
PIER MARIA FORNASARI
2019-09-10

Study shows Mesenchymal Stromal Cells importance of tissue origin in predicting function

A new study released today in STEM CELLS demonstrates that mesenchymal stromal cells (MSCs) expanded from adipose tissue (ASC) outperform those expanded from bone marrow (BM-MSCs). A new study released today in STEM CELLS demonstrates that mesenchymal stromal cells (MSCs) expanded from adipose tissue (ASC) outperform those expanded from bone marrow (BM-MSCs). Importantly, while several

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-09-10

nAngioDerm: European Grant for 3D Printed Skin and Wound Care

The regenerative medicine project nAngioDerm has received a European grant of €747,000 ($822,000) to provide a solution for dermal regeneration, by helping patients whose wounds from ulcers or major burns fail to heal. The funding will go to five European institutions and companies collaborating on the project, which is coordinated by the Institute for Bioengineering of

Read More

No Comments InUncategorized
PIER MARIA FORNASARI
2019-09-10

Exosomes from Adipose-Derived Stem Cells (ADSCs) Overexpressing miR-21 Promote Vascularization of Endothelial Cells

miR-21 has been indicated to be an important regulator of angiogenesis, involving in regulating the proliferation and migration of vascular cells, like endothelial cells. Direct evidences have shown that downregulation of miR-21 expression signifcantly reduces the proliferation and migration of HUVECs, and conversely, miR-21 overexpression signifcantly enhances HUVECs proliferation and migration, indicating the importance of

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-09-10

Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies

Pluripotent stem cells (PSCs) represent an attractive cell source for treating muscular dystrophies (MDs) since they easily allow for the generation of large numbers of highly regenerative myogenic progenitors. Using reprogramming technology, patient-specific PSCs have been derived for several types of MDs, and genome editing has allowed correction of mutations, opening the opportunity for their

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2019-09-10

T-cell therapy receives FDA’s orphan drug status for soft tissue sarcoma

The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas. ADP-A2M4 (Adaptimmune) is an autologous, genetically modified SPEAR T-cell therapy that targets the MAGE-A4 antigen on the surface of cancer cells. Certain soft tissue sarcomas express MAGE-A4 at high levels and

Read More

No Comments InCANCER